Progenics Pharmaceuticals IncFind Ratings Reports
PROGENICS PHARMACEUTICAL INC's gross profit margin for the first quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the industry, the net income growth did not. PROGENICS PHARMACEUTICAL INC is extremely liquid. Currently, the Quick Ratio is 9.06 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 13.97% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY17||Q1 FY16|
|Net Sales ($mil)||2.35||2.45|
|Net Income ($mil)||-16.36||-12.66|
|Balance Sheet||Q1 FY17||Q1 FY16|
|Cash & Equiv. ($mil)||128.01||65.68|
|Total Assets ($mil)||182.85||121.04|
|Total Debt ($mil)||48.85||0.0|
|Profitability||Q1 FY17||Q1 FY16|
|Gross Profit Margin||-558.03||-480.2|
|Return on Assets||3.88||-34.29|
|Return on Equity||7.95||-53.01|
|Debt||Q1 FY17||Q1 FY16|
|Share Data||Q1 FY17||Q1 FY16|
|Shares outstanding (mil)||70.23||69.95|
|Div / share||0.0||0.0|
|Book value / share||1.27||1.12|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||896856.0||1423895.0|
SELL. PROGENICS PHARMACEUTICAL INC's P/E ratio indicates a significant premium compared to an average of 40.44 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 24.41. To use another comparison, its price-to-book ratio of 5.42 indicates a significant premium versus the S&P 500 average of 3.04 and a significant discount versus the industry average of 11.07. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|PGNX 62.64||Peers 40.44||PGNX 33.44||Peers 42.67|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
PGNX is trading at a significant premium to its peers.
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
PGNX is trading at a discount to its peers.
|PGNX NM||Peers 26.63||PGNX NM||Peers 0.54|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
PGNX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
PGNX's negative PEG ratio makes this valuation measure meaningless.
|PGNX 5.42||Peers 11.07||PGNX 118.64||Peers -9.45|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
PGNX is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
PGNX is expected to have an earnings growth rate that significantly exceeds its peers.
|PGNX 6.98||Peers 176.73||PGNX 537.30||Peers 426.84|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
PGNX is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
PGNX has a sales growth rate that significantly exceeds its peers.